贝伐珠单抗联合奥沙利铂为基础化疗一线治疗转移性结直肠癌:一项随机III期研究
该随机III期研究在1401例转移性结直肠癌患者中,采用2×2析因设计比较XELOX与FOLFOX-4并随机加用贝伐珠单抗或安慰剂。贝伐珠单抗组中位无进展生存期9.4个月,安慰剂组8.0个月(HR 0.83;97.5%CI 0.72-0.95;P=0.0023);中位总生存期分别为21.3个月和19.9个月(HR 0.89;97.5%CI 0.76-1.03;P=0.077),缓解率两组相似。
要点
- 贝伐珠单抗联合奥沙利铂为基础化疗显著改善转移性结直肠癌一线治疗的无进展生存期。
- 总生存期差异未达统计学显著,加用贝伐珠单抗未提高缓解率。
- 仅29%贝伐珠单抗组和47%安慰剂组患者治疗至疾病进展。
核心结论
- 在转移性结直肠癌一线治疗中,贝伐珠单抗联合奥沙利铂为基础化疗显著改善无进展生存期。
- 总生存期差异未达统计学显著,加用贝伐珠单抗未改善缓解率。
- 为优化贝伐珠单抗的疗效,可能需要持续治疗至疾病进展。
研究设计与样本
- 随机III期研究,采用2×2析因设计,患者随机分配至XELOX或FOLFOX-4,并随机分配至贝伐珠单抗或安慰剂。
- 共1401例转移性结直肠癌患者纳入2×2分析。
- 主要终点为无进展生存期。
主要发现
- 贝伐珠单抗组中位无进展生存期9.4个月 vs 安慰剂组8.0个月(HR 0.83;97.5%CI 0.72-0.95;P=0.0023)。
- 贝伐珠单抗组中位总生存期21.3个月 vs 安慰剂组19.9个月(HR 0.89;97.5%CI 0.76-1.03;P=0.077)。
- 两组缓解率相似。
- 贝伐珠单抗组29%和安慰剂组47%的患者治疗至疾病进展。
- 贝伐珠单抗的毒性特征与既往试验一致。
临床怎么用
- 原文结论指出,为优化贝伐珠单抗的疗效,可能需要持续治疗至疾病进展。
局限性
- 尽管方案允许治疗持续至疾病进展,但贝伐珠单抗组仅29%、安慰剂组仅47%的患者治疗至疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC). PATIENTS AND METHODS: Patients with MCRC were randomly assigned, in a 2 × 2 factorial design, to XELOX versus FOLFOX-4, and then to bevacizumab versus placebo. The primary end point was progression-free survival (PFS). RESULTS: A total of 1,401 patients were randomly assigned in this 2 × 2 analysis. Median progression-free survival (PFS) was 9.4 months in the bevacizumab group and 8.0 months in the placebo group (hazard ratio [HR], 0.83; 97.5% CI, 0.72 to 0.95; P = .0023). Median overall survival was 21.3 months in the bevacizumab group and 19.9 months in the placebo group (HR, 0.89; 97.5% CI, 0.76 to 1.03; P = .077). Response rates were similar in both arms. Analysis of treatment withdrawals showed that, despite protocol allowance of treatment continuation until disease progression, only 29% and 47% of bevacizumab and placebo recipients, respectively, were treated until progression. The toxicity profile of bevacizumab was consistent with that documented in previous trials. CONCLUSION: The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC. Overall survival differences did not reach statistical significance, and response rate was not improved by the addition of bevacizumab. Treatment continuation until disease progression may be necessary in order to optimize the contribution of bevacizumab to therapy.
引用
- Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol. 2023. PMID: 37459755. doi:10.1200/JCO.22.02760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。